Chapter 16  ·  Module 6  ·  Introduction to Medical Pharmacology

Clinical Pharmacology, Special Populations, and Treatment Algorithms

Treatment-resistant schizophrenia, bipolar disorder, special populations, rapid tranquilization, and prescribing algorithms

Schizophrenia Treatment Algorithm

Step 1 — First Episode

Initial Antipsychotic Selection

  • Choose a second-generation antipsychotic with low extrapyramidal symptom burden
  • Preferred agents: aripiprazole, quetiapine, or risperidone at low doses
  • Avoid clozapine — not appropriate for first episode
  • Discuss long-acting injectable at first episode — do not wait for non-adherence
  • Minimum treatment duration: 1–2 years after first episode

Step 2 — After First Trial

Response Assessment and Next Step

  • Good response, intolerable adverse effects: Switch to agent with better adverse effect profile for the specific problem
  • Inadequate response, tolerable adverse effects: Optimize dose, confirm adherence, then switch mechanistic class
  • No response with confirmed adherence: Advance — do not cycle through more standard agents
  • Confirm adherence before concluding failure

Step 3 — Two Trials Failed

Treatment-Resistant Schizophrenia

  • Two adequate trials failed = clozapine indication
  • Do not delay beyond 2 failed trials
  • Median real-world delay: 4–9 years — a preventable failure
  • Target plasma clozapine level: 350–600 ng/mL before declaring failure
  • Partial response: add amisulpride, aripiprazole, or lamotrigine
  • No response to therapeutic clozapine: electroconvulsive therapy + clozapine

Special Populations — Dose and Agent Adjustments

Population Primary Change Preferred Agent(s) Key Considerations
Hepatic Impairment Reduce dose; slower titration Paliperidone (renally cleared — unaffected) Most antipsychotics require dose reduction in moderate-severe impairment (Child-Pugh B or C)
Renal Impairment Paliperidone dose reduction proportional to creatinine clearance Most agents unaffected Paliperidone 59% renally excreted; risperidone active metabolite also accumulates — reduce dose
Elderly Patients Start at 25–50% of standard dose; titrate slowly Quetiapine (negligible extrapyramidal symptom risk) Reduced hepatic/renal reserve; lower dopamine reserve increases extrapyramidal symptom threshold; increased anticholinergic and orthostatic sensitivity
Dementia Use only after non-pharmacological measures fail Quetiapine (best tolerated) Black-box warning: 1.6–1.7-fold increased all-cause mortality vs. placebo. Lowest effective dose, shortest duration, with regular reassessment
Pregnancy Continue effective treatment — untreated psychosis also carries fetal risk Haloperidol (most pregnancy data); quetiapine or olanzapine (largest second-generation registries) Neonatal adaptation syndrome with third-trimester exposure; monitor neonate at delivery. No agent categorically contraindicated

Rapid Tranquilization — Agent Selection

Agent / Protocol Route and Dose Key Notes
Haloperidol + lorazepam 5 mg IM + 1–2 mg IM First-line; decades of evidence; add diphenhydramine to reduce dystonia risk in antipsychotic-naive patients
Olanzapine IM 10 mg IM NEVER combine with IM or IV benzodiazepines same session — fatal respiratory depression reported. This contraindication is absolute.
Ziprasidone IM 10–20 mg IM Requires prior electrocardiogram — QTc prolongation risk
Inhaled loxapine 10 mg inhaled Rapid onset (~10 min); restricted to settings with bronchospasm management; contraindicated in asthma or chronic obstructive pulmonary disease
Oral/sublingual options Dissolving olanzapine or risperidone solution Use before injection if patient can cooperate with oral medication

Bipolar depression approved agents: Quetiapine (monotherapy), lurasidone (monotherapy or adjunct with lithium or valproate — metabolically favorable), cariprazine (monotherapy — D3 benefit for anergia/anhedonia), olanzapine + fluoxetine combination.

Primary negative symptoms — best pharmacological evidence: Cariprazine (Nemeth et al., Lancet 2017 — only prospective randomized trial powered for primary negative symptom endpoint). Lurasidone secondary benefit via serotonin 5-HT7 antagonism. No other approved agent has Class I evidence for a primary negative symptom endpoint.

Long-acting injectable strategy: Discuss at first episode. Do not wait for documented non-adherence. Biweekly through 6-monthly options available. Frame as a tool for stability, not a consequence of non-compliance.